Real-world evidence to supplement randomized clinical trials: Tocilizumab for severe COVID-19 pneumonia versus a cohort receiving standard of care
Description
Randomized controlled trials (RCT) remain the gold standard for evaluating treatment efficacy, but real-world evidence can supplement RCT results. Tocilizumab was not found to reduce 28-day mortality in a phase 3, double-blind, placebo-controlled
